His scientific interests lie mostly in Immunology, Internal medicine, Acquired immunodeficiency syndrome, Virology and Sida. His work in Immunology addresses issues such as Hazard ratio, which are connected to fields such as Adverse effect and Chemotherapy. The various areas that he examines in his Internal medicine study include Viral load and Zidovudine.
The Acquired immunodeficiency syndrome study combines topics in areas such as Viral disease and Incidence. Bernard Hirschel combines subjects such as Protease inhibitor and Epidemiology with his study of Virology. His Prospective cohort study study deals with Pharmacotherapy intersecting with Coinfection.
His primary areas of investigation include Immunology, Internal medicine, Virology, Acquired immunodeficiency syndrome and Viral load. In general Immunology study, his work on Viral disease, Viremia, CD8 and Immune system often relates to the realm of Institutional repository, thereby connecting several areas of interest. His Internal medicine research includes themes of Gastroenterology, Surgery and Zidovudine.
His Virology study combines topics from a wide range of disciplines, such as Reverse transcriptase, Antigen and Lymph. Sida is the focus of his Acquired immunodeficiency syndrome research. Bernard Hirschel has included themes like Reverse-transcriptase inhibitor, Pharmacotherapy, Combination therapy, Hazard ratio and Indinavir in his Viral load study.
His main research concerns Immunology, Internal medicine, Virology, Viral load and Cohort study. His Immunology research is multidisciplinary, relying on both Transmission, Acquired immunodeficiency syndrome, Antiretroviral therapy and Pediatrics. Many of his studies involve connections with topics such as Gastroenterology and Internal medicine.
The Virology study combines topics in areas such as Hiv infected, Lipodystrophy and Lipoatrophy. He combines subjects such as Interquartile range, Regimen, Tolerability, Combination therapy and Drug resistance with his study of Viral load. His Cohort study research is multidisciplinary, relying on both Body mass index, Pregnancy, Human herpes virus and Population study.
His primary areas of investigation include Immunology, Internal medicine, Cohort study, Viral load and Transmission. His study in the field of Hepatitis C virus is also linked to topics like Neurocognitive. His Internal medicine research includes elements of Gastroenterology, Lopinavir and Surgery.
The concepts of his Cohort study study are interwoven with issues in Condom and Unprotected Sexual Intercourse. His studies deal with areas such as Quantitative trait locus, Viral evolution, Phylogenetics and Heritability as well as Viral load. His Transmission study also includes
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study
Andri Rauch;Zoltán Kutalik;Zoltán Kutalik;Patrick Descombes;Tao Cai.
Gastroenterology (2010)
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.
Gilbert Greub;Bruno Ledergerber;M. Battegay;P. Grob.
The Lancet (2000)
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients : a prospective cohort study
Bruno Ledergerber;Matthias Egger;Milos Opravil;Amalio Telenti.
The Lancet (1999)
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study.
Matthias Egger;Bernard Hirschel;Patrick Francioli;Philippe Sudre.
BMJ (1997)
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia.
Samanta Simioni;Matthias Cavassini;Jean Marie Annoni;Aline Rimbault Abraham.
AIDS (2009)
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
Bruno Ledergerber;M. Egger;V. Erard;R. Weber.
JAMA (1999)
CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years: The Swiss HIV Cohort Study
Gilbert R. Kaufmann;Luc Perrin;Guiseppe Pantaleo;Milos Opravil.
JAMA Internal Medicine (2003)
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Jacques Fellay;Bruno Ledergerber;Enos Bernasconi;Hansjakob Furrer.
The Lancet (2001)
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Gerd Fätkenheuer;Mark Nelson;Adriano Lazzarin;Irina Konourina.
The New England Journal of Medicine (2008)
Turnover of CD4+ and CD8+ T Lymphocytes in HIV-1 Infection as Measured by Ki-67 Antigen
Nicolas Sachsenberg;Alan S. Perelson;Sabine Yerly;Gérard A. Schockmel.
Journal of Experimental Medicine (1998)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Universita della Svizzera Italiana
University of St. Gallen
University Hospital of Basel
Geneva College
University of Bern
Geneva College
University of Zurich
University of Zurich
University of Zurich
University of Lausanne
Amazon (United States)
University of Pennsylvania
Naval Postgraduate School
University of Hong Kong
University of Zaragoza
University of Gothenburg
Marche Polytechnic University
China University of Petroleum, Beijing
Harvard University
Duke University
Oswaldo Cruz Foundation
McGill University
University of California, Los Angeles
Seoul National University Hospital
Monash University
University of California, Davis